Uricosuric medications effective for chronic gout

There was no important difference between benzbromarone and allopurinol at achieving serum urate normalisation, but benzbromarone was probably more successful than probenecid at achieving serum urate normalisation in people with gout. There was some uncertainty around the effect estimates (based on low-quality evidence from only 1 or 2 trials) on the number of acute gout attacks, the number of withdrawals due to adverse events and the total number of participants experiencing adverse events when comparing benzbromarone with allopurinol. However, when compared with probenecid, benzbromarone resulted in fewer withdrawals due to adverse events, and fewer participants experiencing adverse events.